Study identifier:D5135L00003
ClinicalTrials.gov identifier:NCT02227368
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients with Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR
Peripheral Artery Disease (PAD)
Phase 2
No
Ticagrelor, Comparator
All
40
Interventional
50 Years - 130 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jun 2017 by AstraZeneca
AstraZeneca
CPC Clinical Research
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.
A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients with Peripheral Artery Disease Undergoing Endovascular Revascularization – The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR.
Location
Location
Ocala, FL, United States, 34471
Location
Munster, IN, United States, 46321
Location
Sarasota, FL, United States, 34239
Location
New York, NY, United States, 10001
Location
San Antonio, TX, United States, 78229
Location
Daytona Beach, FL, United States, 32114
Location
McKinney, TX, United States, 75069
Location
Jacksonville, FL, United States, 32216
Arms | Assigned Interventions |
---|---|
Experimental: Ticagrelor 26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily | Drug: Ticagrelor Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation. Other Name: Brilinta |
Active Comparator: Aspirin 26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day | Drug: Comparator Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures Other Name: Aspirin |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.